Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a three-day winning streak.
Baird starts Catalyst Pharma with Outperform, $28 target
Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...
Catalyst Pharmaceuticals stock hits all-time high of $24.44
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According to InvestingPro data, the company maintains an "EXCELLENT" financial ...
Forbes4d
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
abrdn plc Buys New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 484,666 shares of the biopharmaceutical company’s stock ...
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.